High level accumulation of EPA and DHA in field‐grown transgenic Camelina – a multi‐territory evaluation of TAG accumulation and heterogeneity
Level 5 - mechanism / opinion, no new human data
Level 5 by design analogy: non-clinical agricultural transgenic plant field experiment with no human data
OpenAlex W3017103971 · doi:10.1111/pbi.13385
What was done
Transgenic *Camelina sativa* carrying a biosynthetic construct (DHA2015.1) was grown in field trials across distinct geographical locations in the UK, USA, and Canada. Researchers analyzed the accumulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) across seed triacylglycerol species and assayed non-seed tissues (leaf, stem, flower, anther, capsule shell) to verify tissue specificity.
What was found
The abstract reports no exact numeric yields or percentages. It notes that the distribution of EPA and DHA across triacylglycerol species followed a consistent trend regardless of the agricultural environment. Neither EPA nor DHA was detected in non-seed tissues, confirming seed-specific accumulation.
Why it matters
Demonstrating stable, seed-specific EPA and DHA production across diverse international field environments supports the feasibility of transgenic oilseed crops as land-based alternatives to ocean-derived fish oils.
Limits
The abstract provides no quantitative data on total lipid yield, individual fatty acid percentages, or crop performance metrics. Long-term multi-generational stability, scalability under commercial farming practices, and non-target ecological impacts were not detailed in the text.
Cited by
- supports Land-based crops including Camelina and soybeans have been genetically engineered to synthesize the marine omega-3 fatty acids EPA and DHA.